TMO EPM / Hemato H9J

TMO EPM / Hemato H9J
  • 0.0 (0)
  • MEDICINE
  • UPDATED WEEKLY

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

  1. 68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    JAN 11

    68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Discussão do artigo: "Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" de Kantarjian H JCO 2024 Apresentado por: Dr. Matheus Garcia Discussão por: Dr. Eduardo Burlamaqui , Dra. Ilana Barcessat, Dra. Amanda Chucre, Dr. Pedro Moraes e Dr. Vinícius Molla

    33 min
  2. 67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

    JAN 7

    67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

    Discussão do artigo: "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma" de Jagannath S JCO 2025 Apresentado por: Dr. Guilherme Rodrigues Discussão por: Dr. Eduardo Burlamaqui, Dra. Ana Cecilia Bahia, Dr. Pedro Moraes e Dr. Vinícius Molla

    24 min
  3. 66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

    12/30/2025

    66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

    Discussão do artigo: "Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study" de Chavez J blood 2025 Apresentado por: Dra. Ilana Barcessat Discussão por: Dr. Rafael Faust , Dra. Ana Cecilia Bahia, Dr. Pedro Moraes e Dr. Vinícius Molla

    27 min
  4. 65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

    11/05/2025

    65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

    Discussão do artigo: "Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma" de Wang M JCO 2025 Apresentado por: Dra. Ana Cecilia Bahia Discussão por: Dr. Gabriele Ritter, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla

    34 min
  5. 64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

    11/02/2025

    64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

    Discussão do artigo: "Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin" de Curtis DJ NEJM 2025 Apresentado por: Dr. Matheus Garcia Discussão por: Dr. Gabrielle Ritter, Dra. Lais Vianna, Dr. Wallber Moraes, Dr. Pedro Moraes e Dr. Vinícius Molla

    39 min
  6. 63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

    09/01/2025

    63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

    Discussão do artigo: "Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT" de DeFilipp Blood 2025 Apresentado por: Dra. Amanda Chucre Discussão por: Dr. Eduardo Burlamaqui, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla

    22 min
  7. 62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation

    08/10/2025

    62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation

    Discussão do artigo: "Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation" de Yao H JCO 2025 Apresentado por: Dra. Ana Cecilia Bahia Discussão por: Dra. Amanda Chucre, Dra. Gabriele Ritter, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla

    31 min
  8. 61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

    08/04/2025

    61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

    Discussão do artigo: "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study" de Zeiser R JCO 2025 Apresentado por: Dra. Amanda Chucre Discussão por: Dra. Ana Cecilia Bahia, Dra. Ilana Barcessat, Dr. Pedro Moraes e Dr. Vinícius Molla

    22 min
See All (68)

About

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

Information

  • Creator
    TMO EPM / Hemato H9J
  • Years Active
    2023 - 2026
  • Episodes
    68
  • Rating
    Clean
  • Copyright
    © TMO EPM / Hemato H9J
  • Show Website
    TMO EPM / Hemato H9J